Cipla posted a consolidated net profit of Rs 789 crore for the fiscal first quarter, down 39 percent from that a year ago. The earnings also fell behind analysts' estimates.Cipla Ltd reported a weaker-than-expected results for the first quarter of FY27, with net profit falling 39 percent year-on-year and missing Street estimates, while revenue growth remained modest and operating margins contracte...

The Nifty 50 succumbed to selling pressure, declining 0.8 percent to end just below the psychological 24,000 mark on July 22, as escalating Middle East tensions lifted oil prices to $95 a barrel. Momentum indicators signal short-term weakness in the market. The index also slipped below its short-term moving averages and the midline of the Bollinger Bands, indicating that bears are in a stronger po...

Equity benchmarks extended their downtrend for a third straight session on July 22, accompanied by weakening market breadth. On the NSE, about 2,120 shares came under pressure, while 875 shares advanced. The market is likely to witness further weakness in the near term amid rising oil prices and escalating geopolitical tensions. Below are some short-term trading ideas to consider:Rupak De, Senior ...

Let's catch up on the latest news from the stock market. From significant investments to major deals, quarterly earnings, order wins, and acquisitions, here’s a quick look at which stocks will be in focus in today's trade:Results TodayInfosys, InterGlobe Aviation, Cipla, Meesh, Motilal Oswal Financial Services, Mphasis, Chennai Petroleum Corporation, Cyient, Indian Energy Exchange, International...

The Nifty Pharma index fell nearly 2 percent to emerge as the worst-performing sectoral index in early trade on Wednesday, with heavyweight drugmakers Sun Pharma, Cipla and Dr Reddy's Laboratories featuring among the top losers on the Nifty 50 after US President Donald Trump unveiled a phased tariff plan for imported generic medicines. The tariff announcement raised concerns over the long-term out...